PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	11	DEC 17	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	12	DEC 17	CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	13	DEC 17	THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS	14	DEC 30	EPFULL: New patent full text database to be available on STN
NEWS	15	DEC 30	CAPLUS - PATENT COVERAGE EXPANDED
NEWS	16	JAN 03	No connect-hour charges in EPFULL during January and February 2005
NEWS	17	JAN 11	CA/CAPLUS - Expanded patent coverage to include Russia (Federal Institute of Industrial Property)

NEWS EXPRESS	JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:32:58 ON 11 JAN 2005

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'STNGUIDE' ENTERED AT 14:33:08 ON 11 JAN 2005

```
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jan  7, 2005 (20050107/UP).

=> FIL HOME
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.06       0.27

FILE 'HOME' ENTERED AT 14:33:12 ON 11 JAN 2005

=> FIL MEDLINE BIOSIS EMBASE CA SCISEARCH
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.48

FILE 'MEDLINE' ENTERED AT 14:33:16 ON 11 JAN 2005

FILE 'BIOSIS' ENTERED AT 14:33:16 ON 11 JAN 2005
Copyright (c) 2005 The Thomson Corporation.

FILE 'EMBASE' ENTERED AT 14:33:16 ON 11 JAN 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'CA' ENTERED AT 14:33:16 ON 11 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 14:33:16 ON 11 JAN 2005
Copyright (c) 2005 The Thomson Corporation.

=> s cd63
L1          3063 CD63

=> s hiv
L2        525566 HIV

=> s l2 and l1
L3            62 L2 AND L1

=> s l3 and py<=2000
   2 FILES SEARCHED...
   4 FILES SEARCHED...
L4            29 L3 AND PY<=2000

=> s l1 and (human immunodef? virus)
   4 FILES SEARCHED...
L5            62 L1 AND (HUMAN IMMUNODEF? VIRUS)

=> s l5 not l2
L6             5 L5 NOT L2

=> s l6 or l4
L7            34 L6 OR L4

=> dup rem l7
PROCESSING COMPLETED FOR L7
L8            14 DUP REM L7 (20 DUPLICATES REMOVED)

=> d l8 ibib abs 1-14

L8   ANSWER 1 OF 14  CA  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         140:320040  CA
```

TITLE: 36Fusion proteins comprising CD1d complex, α2 microglobulin and antibody or fragment for targeting therapy of tumor, autoimmune disease, inflammation and infection

INVENTOR(S): Robert, Bruno; Donda, Alena; Cesson, Valerie; Mach, Jean-Pierre; Zauderer, Maurice

PATENT ASSIGNEE(S): Vaccinex, Inc., USA

SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029206	A2	20040408	WO 2003-US30238	20030926
WO 2004029206	A3	20041007		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1413316	A1	20040428	EP 2002-405838	20020927
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				

PRIORITY APPLN. INFO.: EP 2002-405838 A 20020927

AB The invention is directed to a compound comprising one or more CD1d complexes in association with an antibody specific for a cell surface marker. The CD1d complexes comprise a CD1d, a ss2-microglobulin mol., and may further comprise an antigen bound to the CD1d binding groove. The invention is further directed to methods of inhibiting or stimulating an immune response with the CD1d-antibody compds., in particular anti-tumor and autoimmunity responses.

L8 ANSWER 2 OF 14 CA COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 137:293546 CA

TITLE: Chimeric immunogens targeted to endosomal/lysosomal compartments

INVENTOR(S): August, Thomas; Marques, Ernesto, Jr.

PATENT ASSIGNEE(S): The Johns Hopkins University, USA

SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002080851	A2	20021017	WO 2002-US10757	20020405
WO 2002080851	A3	20030227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1385538	A2	20040204	EP 2002-763958		20020405
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004537285	T2	20041216	JP 2002-578890		20020405
US 2004157307	A1	20040812	US 2004-474371		20040305
PRIORITY APPLN. INFO.:			US 2001-281607P	P	20010405
			US 2001-281608P	P	20010405
			US 2001-281621P	P	20010405
			WO 2002-US10757	W	20020405

AB The authors disclose chimeric proteins comprising an antigen sequence and a domain for trafficking the protein to an endosomal compartment, irresp. of whether the antigen is derived from a membrane or non-membrane protein. In one preferred aspect, the trafficking domain comprises a lumenal domain of a LAMP polypeptide. Alternatively, or addnl., the chimeric protein comprises a trafficking domain of an endocytic receptor (e.g., such as DEC-205 or gp200-MR6). In one example, immune responses to a p55Gag DNA vaccine was enhanced for a construct comprising the Gag protein fused N-terminal to the LAMP-1 protein.

L8 ANSWER 3 OF 14 CA COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 135:15078 CA
TITLE: Fluorescent in situ RT-PCR
INVENTOR(S): Bacallao, Robert; Kher, Rajesh
PATENT ASSIGNEE(S): Advanced Research + Technology Institute, USA
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001042507	A1	20010614	WO 2000-US33460		20001207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 2001030740	A5	20010618	AU 2001-30740		20001207
US 2003059801	A1	20030327	US 2002-149461		20020918
PRIORITY APPLN. INFO.:			US 1999-169750P	P	19991209
			WO 2000-US33460	W	20001207

AB The present invention describes an in situ reverse transcriptase PCR method in which the background fluorescence is greatly reduced as compared to traditional in situ PCR. The fixed permeabilized cells are contacted with at least one restriction endonuclease to produce restriction digests. The cells are then contacted with a DNase to produce DNase digested cells following by incubation with a reverse transcription cocktail to produce a cDNA which is amplified using a PCR reaction. The sections from murine tissues were tested using in situ RT-PCR.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 14 CA COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 133:340273 CA
TITLE: Methods and formulations for targeting infectious

agents bearing host cell proteins
INVENTOR(S): Bergeron, Michel G.; Desormeaux, Andre; Tremblay, Michel J.
PATENT ASSIGNEE(S): Infectio Recherche Inc., Can.
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066173	A2	20001109	WO 2000-CA469	20000503 <--
WO 2000066173	A3	20010809		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2270600	AA	20001103	CA 1999-2270600	19990503 <--
CA 2369550	AA	20001109	CA 2000-2369550	20000503 <--
EP 1173220	A2	20020123	EP 2000-922374	20000503
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002543162	T2	20021217	JP 2000-615056	20000503
AU 768685	B2	20031218	AU 2000-42804	20000503 <--
AU 2000042804	A5	20001117		

PRIORITY APPLN. INFO.: CA 1999-2270600 A 19990503
WO 2000-CA469 W 20000503

AB A formulation is disclosed for the treatment of diseases caused by an infectious agent which acquires host membranes protein during its life cycle. The formulation is a targeting pharmaceutical composition It comprises a ligand capable of binding the host membrane proteins coupled to a lipid-comprising vesicle, which may comprise or not a drug effective in the treatment of the disease. Specific liposomes bearing anti-HLA-DR or anti-CD4 antibodies comprising or not antiviral drugs, namely anti-**HIV** drugs, are disclosed and claimed. A method of formulation as well as a method of using the formulation in the treatment of a disease are also disclosed.

L8 ANSWER 5 OF 14 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
ACCESSION NUMBER: 2000:384795 BIOSIS
DOCUMENT NUMBER: PREV200000384795
TITLE: Hypericin inactivates viruses in platelet concentrates.
AUTHOR(S): Seifried, E. [Reprint author]; Mueller, M. [Reprint author]; Willkommen, H.; Scheiblauer, H.; Norley, S.; Kirchmaier, C. M. [Reprint author]
CORPORATE SOURCE: RC Blood Donor Service Center, Inst. Transfusion Medicine/Immunohaematology, Frankfurt, Germany
SOURCE: Vox Sanguinis, (July, 2000) Vol. 78, No. Suppl. 1, pp. O104. print.
Meeting Info.: 26th Congress of the International Society of Blood Transfusion. Vienna, Austria. July 09-14, 2000. International Society of Blood Transfusion.
CODEN: VOSAAD. ISSN: 0042-9007.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English

ENTRY DATE: Entered STN: 6 Sep 2000
Last Updated on STN: 8 Jan 2002

L8 ANSWER 6 OF 14 CA COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 130:264436 CA
TITLE: Methods of replicating virus in monocyte-derived macrophage cultures
INVENTOR(S): Soderberg-naucler, Cecilia; Fish, Kenneth N.; Moses, Ashlee; Streblow, Daniel; Nelson, Jay
PATENT ASSIGNEE(S): Oregon Health Sciences University, USA
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9916891	A1	19990408	WO 1998-US20749	19980930
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2305622	AA	19990408	CA 1998-2305622	19980930
AU 9895993	A1	19990423	AU 1998-95993	19980930
AU 738685	B2	20010927		
EP 1023451	A1	20000802	EP 1998-949728	19980930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6225048	B1	20010501	US 1998-164221	19980930
JP 2001518306	T2	20011016	JP 2000-513960	19980930
US 2001055755	A1	20011227	US 2001-810328	20010315

PRIORITY APPLN. INFO.: US 1997-60583P P 19971001
US 1998-164221 A1 19980930
WO 1998-US20749 W 19980930

AB The present invention provides methods of latent virus reactivation in monocyte-drived macrophages through allogeneic stimulation of peripheral blood mononuclear cells (PBMC), methods of culturing virus, and cultures of virally permissive monocyte-derived macrophages. To determine whether cytokines or other soluble factors are sufficient to differentiate monocytes to human cytomegalovirus-permissive monocyte-derived macrophages (MDM), allogeneically stimulated MDM conditioned culture medium was used to differentiate CD14+ monocytes obtained from naturally infected seropos. donors. A transwell system was used to sep. the monocytes from a single seropos. donor from an allo-reaction of two seroneg. donors. Conditioned medium was sufficient to differentiate monocytes into MDM with a similar morphol. and viral permissiveness as the parallel allo-MDM cell cultures.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 14 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
ACCESSION NUMBER: 1999214845 EMBASE
TITLE: [Evaluation of allergic-type reactions to antimicrobials and rush immunotherapy].
BILAN DES REACTIONS DE TYPE ALLERGIQUE AUX ANTIBIOTIQUES ET ACCOUTUMANCE RAPIDE.
AUTHOR: Brunet J.L.; Boibieux A.; Biron F.; Bouhour D.; Cozon G.; Sainte-Laudy J.; Chidiac C.; Peyramond D.

CORPORATE SOURCE: J.L. Brunet, Service des Maladies Infectieuses, Hopital de la Croix-Rousse, 69317 Lyon Cedex 04, France
SOURCE: Pathologie Biologie, (1999) 47/5 (491-493).
Refs: 5
ISSN: 0369-8114 CODEN: PTBIAN
COUNTRY: France
DOCUMENT TYPE: Journal; Conference Article
FILE SEGMENT: 004 Microbiology
026 Immunology, Serology and Transplantation
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: French
SUMMARY LANGUAGE: English; French
AB Adverse effects of medications, most notably antimicrobials, are becoming increasingly common and raise difficult challenges in the area of clinical pattern definition (wide variety of symptoms, polypharmacy in many cases), diagnosis, and methodology (need for a rapid diagnosis, frequent obscurity of causative mechanisms, and less than ideal reliability of laboratory techniques). Sixty patients were treated by rush immunotherapy to one or more antimicrobials. The pretreatment evaluation included oriented history taking, skin tests, blood cell counts, IgE assays, and cell activation tests (basophils and lymphocytes). The results of this study confirm the usefulness of skin tests (intradermal, prick, or patch tests), which provided etiological orientation in 54 of the 60 cases. They also provide additional evidence of the lack of reliability of currently available in vitro tests (only 29 of the 60 tests were positive).

L8 ANSWER 8 OF 14 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
ACCESSION NUMBER: 1999:167004 BIOSIS
DOCUMENT NUMBER: PREV199900167004
TITLE: Regulation of class II production after **HIV**-1 infection.
AUTHOR(S): Kraus, T.; Chen, H.; Becker, K.; Rakoff, K. S.; Sperber, K.
CORPORATE SOURCE: Mt. Sinai Sch. Med., New York, NY 10029, USA
SOURCE: FASEB Journal, (March 12, 1999) Vol. 13, No. 4 PART 1, pp. A292. print.
Meeting Info.: Annual Meeting of the Professional Research Scientists for Experimental Biology 99. Washington, D.C., USA. April 17-21, 1999.
CODEN: FAJOEC. ISSN: 0892-6638.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 19 Apr 1999
Last Updated on STN: 19 Apr 1999

L8 ANSWER 9 OF 14 CA COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 129:92575 CA
TITLE: Method for characterization of abnormal cells using multiple antibody- or ligand-coated particles
INVENTOR(S): Fodstad, Oystein; Hoifodt, Hanne Kleppe
PATENT ASSIGNEE(S): Norway
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9828622	A1	19980702	WO 1997-NO342	19971216 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,

DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,
US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
GA, GN, ML, MR, NE, SN, TD, TG

NO 9605531	A	19980622	NO 1996-5531	19961220 <--
CA 2275335	AA	19980702	CA 1997-2275335	19971216 <--
AU 9878752	A1	19980717	AU 1998-78752	19971216 <--
AU 728190	B2	20010104		
EP 951645	A1	19991027	EP 1997-949270	19971216 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

PRIORITY APPLN. INFO.:	NO 1996-5531	A	19961220
	WO 1997-NO342	W	19971216

AB A method to detect and phenotype target cells in cell suspensions uses particles coated with antibodies/ligands directed to antigenic determinants/receptors expressed on the target cells. The method is characterized in that several types of particles are used and each type of particle is instrumentally or visually separable by fluorescence, color and size. Each type of particle is coated with a different antibody or ligand. The particles are incubated simultaneously or sequentially with cell suspensions containing the target cells, in connection or not with a per se known enrichment procedure. A kit using the method is also disclosed. A suspension of ascitic cells was incubated with different antibody-coated fluorescent particles and paramagnetic immunobeads. The cells were determined to be malignant and epithelial in nature based on the antibody particles that bound to the cells.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 14 MEDLINE on STN DUPLICATE 1

ACCESSION NUMBER:	1998099250 MEDLINE
DOCUMENT NUMBER:	PubMed ID: 9438413
TITLE:	Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection.
AUTHOR:	Holme P A; Muller F; Solum N O; Brosstad F; Froland S S; Aukrust P
CORPORATE SOURCE:	Research Institute for Internal Medicine, Medical Department A, The National Hospital, University of Oslo, Norway.
SOURCE:	FASEB journal : official publication of the Federation of American Societies for Experimental Biology, **(1998 Jan)** 12 (1) 79-89. Journal code: 8804484. ISSN: 0892-6638.
PUB. COUNTRY:	United States
DOCUMENT TYPE:	Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:	English
FILE SEGMENT:	Priority Journals; AIDS
ENTRY MONTH:	199802
ENTRY DATE:	Entered STN: 19980224 Last Updated on STN: 19980224 Entered Medline: 19980209

AB Besides their role in hemostasis, platelets are involved in inflammatory and immunological processes, and we hypothesize that platelet activation may play an immunopathogenetic role in **HIV**-1 infection. Blood was drawn from 15 controls and 20 **HIV**-1-infected patients with normal platelet counts, classified into groups of non-AIDS and AIDS. Platelet activation was detected using flow cytometry with mAbs against the release markers P-selectin and **CD63**, mAb against GPIb, and the probe annexin V detecting surface exposure of aminophospholipids. The amount of microvesicles was measured using mAb against GPIIIa. Compared to controls, blood samples from **HIV**-1-infected patients showed

significantly enhanced levels of microvesicles and activated platelets as detected by their exposure of P-selectin, **CD63**, and aminophospholipids, as well as reduction in GPIb expression. Increased expression of P-selectin and amounts of microvesicles were most pronounced in advanced clinical and immunological disease. When studying the effect of **HIV**-1 protease inhibitor therapy (indinavir) on platelet activation, we found that concomitant with a profound decrease in plasma viral load, there was a near normalization of several of the parameters reflecting enhanced platelet activation. Finally, we demonstrated that platelets may be an important source of the chemokine RANTES in **HIV**-1-infected patients. Although both unstimulated and SFLLRN-stimulated platelets from asymptomatic patients had enhanced release of RANTES, platelets from AIDS patients were characterized by markedly enhanced spontaneous, but decreased SFLLRN-stimulated release of this chemokine. Taken together, these results, which demonstrate for the first time increased platelet activation in **HIV**-1-infected patients with normal platelet counts, may represent a previously unrecognized immunopathogenic factor in **HIV**-1 infection.

L8 ANSWER 11 OF 14 MEDLINE on STN DUPLICATE 2
ACCESSION NUMBER: 97271317 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9126268
TITLE: Cell membrane vesicles are a major contaminant of gradient-enriched human immunodeficiency virus type-1 preparations.
AUTHOR: Gluschankof P; Mondor I; Gelderblom H R; Sattentau Q J
CORPORATE SOURCE: Centre d'immunologie de Marseille-Luminy, France.. gluschan@ciml.univ-mrs.fr
SOURCE: Virology, **(1997 Mar 31)** 230 (1) 125-33. Journal code: 0110674. ISSN: 0042-6822.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals; AIDS
ENTRY MONTH: 199706
ENTRY DATE: Entered STN: 19970709
Last Updated on STN: 19970709
Entered Medline: 19970626

AB During preliminary experiments to establish the proportion of virus-coded p24 protein to virus membrane-associated HLA-DR in gradient-enriched **HIV**-1 preparations, we became aware of a large variability between experiments. In order to determine whether HLA-DR-containing cellular material was contaminating the virus preparations, we carried out enrichment by gradient centrifugation of clarified supernatants from noninfected cells and tested this material for HLA-DR content. We found that, independently of the cell type used, gradient enrichment resulted in the isolation of large quantities of HLA-DR-containing material which banded at a density overlapping that of infectious **HIV.** Electron microscopy of gradient-enriched preparations from supernatants of virus-infected cells revealed an excess of vesicles with a size range of about 50-500 nm, as opposed to a minor population of virus particles of about 100 nm. Electron micrographs of infected cells showed polarized vesiculation of the cell membrane, and virus budding was frequently colocalized with nonviral membrane vesiculation. Analysis of the cellular molecules present in the fractions containing virus or exclusively cellular material demonstrated that virus and cellular vesicles share several cellular antigens, with the exception of CD43 and **CD63**, found mainly at the virus surface, and HLA-DQ, which was found only in the cellular vesicles.

L8 ANSWER 12 OF 14 MEDLINE on STN DUPLICATE 3
ACCESSION NUMBER: 94145751 MEDLINE
DOCUMENT NUMBER: PubMed ID: 8312057
TITLE: Association of host cell surface adhesion receptors and

other membrane proteins with **HIV** and SIV.
AUTHOR: Orentas R J; Hildreth J E
CORPORATE SOURCE: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
CONTRACT NUMBER: 5 R01 AI 31806 (NIAID)
5 T32 CA 09243 (NCI)
SOURCE: AIDS research and human retroviruses, **(1993 Nov)** 9 (11) 1157-65.
Journal code: 8709376. ISSN: 0889-2229.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals; AIDS
ENTRY MONTH: 199403
ENTRY DATE: Entered STN: 19940330
Last Updated on STN: 19970203
Entered Medline: 19940318

AB We have developed a MAb-based capture assay to study the association of host cell membrane proteins with **HIV** and SIV. Class I and II MHC proteins were found to be associated with **HIV** as previously described. In addition to these molecules a number of other host molecules were found to be acquired by **HIV**, including CD71, **CD63**, CD43, and CD8. We have demonstrated that the major leukocyte adhesion receptors LFA-1 (CD11A/CD18) and CD44 are also associated with **HIV**. The level of surface expression of host membrane proteins did not predict relative expression (capture efficiency) of the virus. The use of virus-susceptible indicator cells showed that the assay involved host membrane protein-mediated capture of infectious **HIV** and SIV particles. Our data indicate that **HIV** and SIV acquire a number of host membrane proteins including adhesion receptors and that this process may be nonrandom. The acquisition of host cell adhesion receptors by **HIV** and SIV could have profound effects on the biology of the viruses, including binding, infectivity, and tropism.

L8 ANSWER 13 OF 14 MEDLINE on STN DUPLICATE 4
ACCESSION NUMBER: 93139775 MEDLINE
DOCUMENT NUMBER: PubMed ID: 8093711
TITLE: Host cell membrane proteins on human immunodeficiency virus type 1 after in vitro infection of H9 cells and blood mononuclear cells. An immuno-electron microscopic study.
AUTHOR: Meerloo T; Sheikh M A; Bloem A C; de Ronde A; Schutten M; van Els C A; Roholl P J; Joling P; Goudsmit J; Schuurman H J
CORPORATE SOURCE: Department of Pathology, University Hospital, Utrecht, The Netherlands.
SOURCE: Journal of general virology, **(1993 Jan)** 74 (Pt 1) 129-35.
Journal code: 0077340. ISSN: 0022-1317.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals; AIDS
ENTRY MONTH: 199302
ENTRY DATE: Entered STN: 19930312
Last Updated on STN: 19970203
Entered Medline: 19930222

AB Human immunodeficiency virus type 1 (**HIV**-1)-infected H9 and blood mononuclear cells (MNCs) were studied by immunogold electron microscopy for the presence of **HIV**-1 gag p24 protein, env gp41 and gp120 proteins, and host cell molecules CD4, CD11a, CD25, CD54, **CD63**, HLA class I and HLA-DR. Uninfected H9 cells and MNC membranes labelled for CD4, HLA class I and class II, and, at low density,

CD11a and CD54; lysosomal structures in the cytoplasm labelled for **CD63**. The infected cell surface showed immunolabelling for **HIV**-1 proteins, as did budding particle-like structures. Immunogold labelling of the cell membrane for CD4 was almost non-existent. The level of immunolabelling for CD11a and CD54 on infected cells was greater than that on uninfected cells; this is presumably related to a state of activation during virus synthesis. Budding particle-like structures and free virions in the intercellular space were immunogold-labelled for all host cell markers investigated. This was confirmed by double immunogold labelling using combinations of **HIV** -1 gag p24 labelling and labelling for the respective host cell molecule. We conclude that virions generated in **HIV**-1-infected cells concentrate host-derived molecules on their envelope. Also molecules with a prime function in cellular adhesion concentrate on the virion.

L8 ANSWER 14 OF 14 MEDLINE on STN DUPLICATE 5
ACCESSION NUMBER: 93103619 MEDLINE
DOCUMENT NUMBER: PubMed ID: 1466841
TITLE: Modulation of cell surface molecules during **HIV**-1 infection of H9 cells. An immunoelectron microscopic study.
AUTHOR: Meerloo T; Parmentier H K; Osterhaus A D; Goudsmit J; Schuurman H J
CORPORATE SOURCE: Department of Pathology, University Hospital, Utrecht, The Netherlands.
SOURCE: AIDS (London, England), **(1992 Oct)** 6 (10) 1105-16.
Journal code: 8710219. ISSN: 0269-9370.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals; AIDS
ENTRY MONTH: 199301
ENTRY DATE: Entered STN: 19930212
Last Updated on STN: 19970203
Entered Medline: 19930128

AB OBJECTIVE: To study cell surface molecules and **HIV**-1 proteins on H9 cells 2 days after infection by immunogold electron microscopy, either in single or in double labelling using combinations of host cell-derived molecules and **HIV**-1 proteins. DESIGN AND METHODS: The presence of host cell antigens CD3, CD4 and human leukocyte antigen-DR (HLA-DR) and **HIV**-1 antigens gag p15, p17, p24 and env gp41 was evaluated using immunocytochemistry at the light microscopic level. H9 cells 2 days after infection were processed for conventional transmission electron microscopy and cryo-ultramicrotomy. Leukocyte antigens investigated were CD2, CD3, CD4 (two antibodies), CD5, CD8, CD25, CD30, **CD63** antigens and HLA-DR; **HIV**-1-encoded antigens were gag p24, pol reverse transcriptase, and env gp41 and gp120. Double immunogold labelling was performed using reagents with different sized gold particles. For leukocyte markers, the labelling density of the cell membrane was assessed quantitatively on uninfected and infected H9 cells. RESULTS: Infected cells revealed the presence of gag p24, pol, and env gp41 and gp120 antigens on **HIV**-1 virions. Uninfected H9 cells showed a random distribution of cell surface molecules, including CD4 antigen, along the plasma membrane. The **CD63** antigen, a lysosomal membrane glycoprotein, was located mainly in the cytoplasm of uninfected cells. Cells 2 days after infection showed CD4 labelling on sites where virions were budding from or attached to the cell surface and on free virions. Virions also showed labelling by CD3, CD5, CD25, CD30 and **CD63** antibodies and anti-HLA-DR. Compared with uninfected cells, a significantly lower density was found on infected cells in labelling for CD4, CD5 and anti-HLA-DR. A significantly higher density on cells 2 days after infection was seen in **CD63** labelling. CONCLUSION: During the first phase of infection host cell molecules concentrate on budding structures and newly generated **HIV**-1 virions. This phenomenon

might contribute to the disappearance of these molecules (like the CD4 molecule) from the cell membrane after infection.

```
=> s HAVEL, P?/au;s EVANS, J?/au
L9          573 HAVEL, P?/AU


L10       20850 EVANS, J?/AU

=> d his

     (FILE 'HOME' ENTERED AT 14:32:58 ON 11 JAN 2005)

     FILE 'STNGUIDE' ENTERED AT 14:33:08 ON 11 JAN 2005

     FILE 'HOME' ENTERED AT 14:33:12 ON 11 JAN 2005

     FILE 'MEDLINE, BIOSIS, EMBASE, CA, SCISEARCH' ENTERED AT 14:33:16 ON 11
     JAN 2005
L1          3063 S CD63
L2        525566 S HIV
L3            62 S L2 AND L1
L4            29 S L3 AND PY<=2000
L5            62 S L1 AND (HUMAN IMMUNODEF? VIRUS)
L6             5 S L5 NOT L2
L7            34 S L6 OR L4
L8            14 DUP REM L7 (20 DUPLICATES REMOVED)
L9           573 S HAVEL, P?/AU
L10        20850 S EVANS, J?/AU

=> s l1 and (l9 or l10 )
L11            0 L1 AND (L9 OR L10 )

=> s l2 and (l9 or l10)
L12          119 L2 AND (L9 OR L10)

=> s l12 and l1
L13            0 L12 AND L1

=> s l8 and (antibod? or anti-bod?)
L14            7 L8 AND (ANTIBOD? OR ANTI-BOD?)

=>

---Logging off of STN---


=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               55.16      55.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                               -4.08      -4.08

STN INTERNATIONAL LOGOFF AT 14:40:26 ON 11 JAN 2005
```